Key result
Genetic testing in early-onset atrial fibrillation represents a potential clinical opportunity that currently lacks definitive proof of benefit.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Garcia et al. (2026) studied this question. Genetic testing in early-onset atrial fibrillation represents a potential clinical opportunity that currently lacks definitive proof of benefit.
Synapse has enriched 10 related papers. Consider them for comparative context: